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Abstract
Rationale High levels of impulsivity have been associated
with psychiatric disorders such as attention-deficit/hyperactiv-
ity disorder (ADHD) and substance abuse. In addition, acute
stress is known to exacerbate many psychiatric symptoms in
impulse control disorders.
Objectives The purpose of the current study was to investigate
the acute effects of the pharmacological stressor yohimbine on
response inhibition and impulsive choice.
Methods A group of male rats (n=12) was trained in the
delayed reward task (DRT) to assess impulsive choice. A sep-
arate group (n=10) was trained in the stop-signal task (SST)
to measure response inhibition. Upon stable responding, the
effects of yohimbine (0, 1.25, 2.5, and 5 mg/kg i.p.) were
tested in a Latin square design.
Results Acute yohimbine significantly increased the prefer-
ence for the large and delayed reinforcer in the DRT, indicat-
ing a decrease in impulsive choice. On the contrary, the effect
size of 1.25 mg/kg yohimbine on stop-signal reaction times
correlated negatively with baseline performance, suggesting a
baseline-dependent effect on response inhibition as measured
in the SST.
Conclusions The current data suggest that the effects of the
pharmacological stressor yohimbine on impulse control
strongly depend on the type of impulsive behavior.
Pharmacological stress decreased impulsive decision making,
an observation that is in line with previously published rodent
studies. By contrast, the lowest dose of yohimbine revealed a
baseline-dependent effect on response inhibition. As such, the
effects of yohimbine are largely comparable to the effects of
psychostimulants on impulsivity and may support the notion
of cross sensitization of stress and psychostimulants.
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Introduction
Maladaptive impulsive behavior is associated with many psy-
chiatric disorders, such as drug addiction, obsessive-
compulsive disorder, attention-deficit/hyperactivity disorder
(ADHD), bipolar disorder, and pathological gambling
(Fineberg et al. 2014; Moeller et al. 2001; Pattij and De
Vries 2013). In addition, acute stress is known to exacerbate
many psychiatric symptoms in impulse control disorders
(Roberts et al. 2009). However, the role of acute stress in
impulsive behavior has not been well characterized.
Impulsivity is a multifaceted concept (Evenden 1999), and
it has been recognized that different forms of impulsive be-
havior can be dissociated on a neuroanatomical, neurophar-
macological, and behavioral level (Evenden 1999; Pattij and
Vanderschuren 2008). In this regard, two main forms of im-
pulsive behavior have been recognized, namely, impulsive
action and impulsive choice, which do not correlate on the
individual level, suggesting distinct underlying neural mech-
anisms (Broos et al. 2012; Robinson et al. 2009; Solanto et al.
2001). Of these, the former can be defined as difficulties to
inhibit either inappropriate or planned motor responses. The
latter, impulsive choice is defined as the preference for a small
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immediate reward over a delayed but more beneficial reward.
Since acute stress is possibly related to maladaptive impulsive
behavior, the characterization of the effects of stress on differ-
ent forms of impulsivity is of high importance, in order to
provide a better understanding of the underlying neurobiolog-
ical mechanisms and to eventually improve treatment
opportunities.
Acute stress downregulates presynaptic α2 adrenergic re-
ceptors (Flugge et al. 2004), thereby increasing noradrenergic
signaling (Abercrombie et al. 1988), which is suggested to be
mimicked by the competitive α2 adrenoceptor antagonist yo-
himbine. This compound, yohimbine, is frequently used as a
pharmacological agent to study acute stress effects, since the
compound can be studied across species and provides the
opportunity to titrate stress with varying doses. In humans, it
has been shown that the administration of yohimbine leads to
panic and anxious feelings, increased heart rate, and increased
cortisol measures and noradrenaline metabolite levels (Bourin
et al. 1998; Charney et al. 1984; Stine et al. 2002; Swann et al.
2005).
Several preclinical studies have shown that yohimbine in-
creases impulsive action in the 5-choice serial reaction time
task (5-CSRTT) in rats (Sun et al. 2010; Torregrossa et al.
2012) and the rat gambling task (Connolly et al. 2015), obser-
vations that are confirmed clinically in the continuous perfor-
mance task (Swann et al. 2005; Swann et al. 2013). Recently,
yohimbine has been reported to decrease impulsive choice in
rats as measured in the delayed reward task (DRT) (Schwager
et al. 2014), in contrast to the clinical observations on impul-
sive decision making which report increases by stress (Fields
et al. 2014; Kimura et al. 2013; Lempert et al. 2012; Porcelli
and Delgado 2009; Putman et al. 2010). Taken together, stress
seems to increase some forms of impulsive behavior; howev-
er, this could not be confirmed in a preclinical DRT.
Despite the fact that yohimbine has been shown to impair
measures of action impulsivity, this is the first study to explore
its effects in the stop-signal task (SST). Although response
inhibition is a form of impulsive action, it is conceptually
different from impulsive action as measured in the 5-
CSRTT. In the SST, a task which assesses response inhibition,
estimated stop-signal reaction times are an indication of action
cancellation (Verbruggen and Logan 2008), whereas prema-
ture responses in the 5-CSRTT reflect the inability to inhibit
prepotent actions (Robbins 2002).
The purpose of the current study was to investigate the
effects of the pharmacological stressor yohimbine on different
forms of impulsive behavior. More specifically, we examined
the effect of yohimbine on response inhibition and impulsive
choice in two translational rodent paradigms. To this end,
impulsive choice was measured using the DRT, a task in
which rats are allowed to choose a small immediate or large
delayed reward. The SSTwas used to measure response inhi-
bition. Upon stable baseline performance in the two tasks, the
effects of yohimbine on measures of impulsive behavior were
tested. Based on previous preclinical findings with acute yo-
himbine on different impulsivity tasks (Connolly et al. 2015;
Schwager et al. 2014; Sun et al. 2010; Torregrossa et al. 2012),
we hypothesized that the administration of yohimbine will




Twenty-four male Wistar rats (Harlan, Horst, the
Netherlands) weighing 250–275 g at the start of the ex-
periment served as the subjects and were run in two sep-
arate experimental groups. The rats were housed in pairs
in enriched Makrolon cages and kept under standard
housing conditions under a reversed 12-h light/dark
schedule (lights on at 19:00 h). For the purpose of the
behavioral tasks, the animals were food restricted and
maintained at 90 % of their free-feeding body weight.
Water was available ad libitum. All experiments were ap-
proved by the Animal Ethical Committee of the VU




Both tasks were conducted in 12 identical operant cham-
bers (Med Associates Inc., St. Albans, USA) which were
housed in sound-attenuating ventilated cubicles. One wall
contained an array of five nose poke holes that could be
illuminated and had an infrared beam for nose poke de-
tection. On the opposite wall, a food magazine was situ-
ated, where the reward (45-mg precision pellets; BioServ,
Frenchtown, USA) was delivered. A white house light
was situated on the same wall as the food tray.
Delayed reward task
A detailed description of the delayed reward paradigm as
employed in our laboratory has been described previously
(van Gaalen et al. 2006b). For the purpose of the DRT, nose
poke holes 2, 3, and 4 in the operant chambers were used.
After habituating the rats to the operant chambers and food
pellets, the animals were trained to make a nose poke in one of
the three holes, which resulted in a delivery of a food pellet.
Next, the animals were required to first make a response in the
central unit, followed by a response in either the left or right
unit, which resulted in a delivery of a food pellet. In the
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following stages of training, each session was divided into 5
blocks of 12 trials, each block starting with 2 forced trials,
during which, after initiating the trial through a nose poke into
the central unit, either the left unit or the right unit was illu-
minated in a counterbalanced fashion. In the next 10 trials, the
animals had a free choice and both the left and right units were
illuminated. Poking into one position resulted in the immedi-
ate delivery of a small reinforcer (one food pellet), whereas a
nose poke into the other position resulted in the delivery of a
large, but delayed, reinforcer (four food pellets). Over ses-
sions, the within-session delays for the large reinforce were
increased to 0, 5, 10, 20, and 40 s per block. If an animal did
not make a response during this choice phase within 10 s, an
intertrial interval (ITI) was initiated and the trial was counted
as an omission. The position associated with the small and
large reinforcer was always the same for each individual and
counterbalanced for the group of rats. Responding into non-
illuminated units during the test was recorded but had no
further programmed consequences. The behavioral measure
to assess task performance, i.e., the percentage preference
for the large reinforcer as a function of delay, was calculated
per delay block of 10 trials within a session as the number of
choices for the large reinforcer choices/(number choices large
+ small reinforcers) × 100. In addition, the total number of
omitted started trials and choice trials per block of 10 trials
within a session and the average response latencies to start a
trial and to make a response in the nose poke hole associated
with the small and large rewards after onset of the stimulus
light in the corresponding hole were calculated. Furthermore,
hyperbolic curves for the percentage preference were fitted on
the individual data by the equation V=A/(1+ kD), where V is
the preference for the large reward after a delay of D in sec-
onds, A is the preference for the large reward at D=0 s, and k
describes the steepness of the discounting curve (Mazur
2006). Based on the estimated hyperbolic curve, the indiffer-
ence point, the delay for which the rats switched their prefer-
ence over to the immediate, small reward (i.e., the delay on
which the preference for large reward <50 %) was calculated.
Stop-signal task
Shaping For the purpose of the stop-signal task, only nose
poke hole 3 and one of the outer right or left holes were used
(counterbalanced for all subjects). The stop-signal task as
employed in our laboratory has been described more elabo-
rately elsewhere (Pattij et al. 2009). Briefly, during initial
shaping for two consecutive sessions, both the middle nose
poke hole and the outer holes to the right or left were illumi-
nated. A nose poke into either one of the two active holes
extinguished the visual stimuli in both holes and resulted in
delivery of a pellet. After an ITI of 30 s, the next trial started.
Nose poking within this ITI period did not have any
programmed consequences. A session ended after 30 min or
100 trials, whichever occurred first.
Shaping: go trials During the next phase, only the stimulus
light in the middle nose poke hole was illuminated (start stim-
ulus). A response into the active middle hole switched off the
stimulus light and was followed by the illumination of the
stimulus light (go stimulus) in the outer left or right hole. A
nose poke into the illuminated hole switched off the stimulus
light and resulted in the delivery of a pellet. After an ITI of 5 s,
the next trial started. Responding in the start stimulus hole
during the presentation of the go stimulus was counted as
perseverative start pokes, whereas prestimulus responses into
the go stimulus hole resulted in a time-out period of 5 s.
Subsequently, the response requirements into the start stimu-
lus hole before the onset of a go stimulus were varied into a
variable ratio 2 schedule (VR2, i.e., either FR1, FR2, or FR3)
to avoid the development of a prepotent response pattern from
the start stimulus to the go stimulus hole and to ensure that the
animals waited until the appearance of a go stimulus. During
this phase, the rats were trained until they reliably completed
100 successful go trials. Following this phase, a limited hold
period was introduced for the go stimulus and only during this
period was the go stimulus present. Initially, the limited hold
was set at 5 s, and in subsequent sessions, was individually
titrated to meet performance criterion of 80 % successful hits
and <20 % prestimulus responses. Omissions of a go stimulus
response within the limited hold resulted in a 5-s time-out
period, during which both the house light and stimulus light
were turned off.
Shaping: introduction stop signal During the final training
phase, a stop signal was introduced in 25 % of all trials.
Initially, this stop signal (duration 50 ms, frequency
4500Hz, and intensity 80 dB) was contingent with the appear-
ance of the go signal. Responding during the onset of the stop
signal or during the limited hold immediately extinguished the
go stimulus and house light, turned off the stop signal, and
was followed by a 5-s time-out. In contrast, if the animal
successfully refrained from responding during a stop trial, a
pellet was delivered. Initially, the limited hold during stop and
go trials were equal; however, when performance during stop
trials was below 80 % successfully inhibited stop trials, the
limited hold during stop trials was lowered over sessions in
steps of 50–100 ms until animals improved performance.
Subsequently, the limited hold was then gradually increased
in these individuals over sessions until the limited hold during
both the go and stop trials were equal. As soon as animals
reached the criterion of approximately 90 % successfully
inhibited stop trials, delays for the onset of the stop signal
were introduced. The stop-signal delays (SSDs) were present-
ed in a pseudorandom order, and to compensate for differ-
ences between rats, SSDs were based on each individual rat’s
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mean reaction time on go trials in the preceding drug-free
training session. SSDs were calculated as follows: mean go
reaction time (mean GoRT) minus either 50, 75, 150, 300, and
500 ms. In addition, an equal amount of zero delays were
presented during sessions. Drug testing commenced upon sta-
ble baseline performance for at least five consecutive sessions,
i.e., 80 % accuracy during go trials and a significant SSD-
dependent decrease in correctly inhibited stop trials.
Stop-signal paradigm: estimation stop-signal reaction
time and correction for omissions during go trials Stop-
signal reaction times (SSRTs) were estimated with the integra-
tion method, which is less influenced by skewness of the
reaction time distribution (Verbruggen et al. 2013). The per-
formance of the rats was analyzed according to the assump-
tions of the race model, which assumes that go and stop pro-
cesses are independent from each other (Logan and Cowan
1984).
Drugs
Yohimbine hydrochloride (Sigma, St. Louis, MO, USA) was
dissolved in distilled water. On test days, yohimbine was
freshly prepared and intraperitoneally injected in a volume
of 1-ml/kg body weight according to a Latin square within-
subject design. Doses (1.25, 2.5, and 5 mg/kg) were based on
previous studies investigating the effects of acute yohimbine
administration on impulsive behavior (Schwager et al. 2014;
Sun et al. 2010; Torregrossa et al. 2012). Upon stable baseline
responding and prior to pharmacological challenges, the rats
were habituated to the injection procedures to rule out possible
stressful effects of the injection. In all experiments, vehicle or
yohimbine was administered 30 min before testing on
Tuesdays and Fridays with baseline training sessions on the
other weekdays.
Statistical analyses
All data are presented as mean± standard errors of the mean.
Data were analyzed with repeated measures analysis of vari-
ance (ANOVA) with drug dose, delay for the large reward
(DRT), and SSD (SST) as within-subject variables using
IBM SPSS Statistics version 20 (IBM, New York, USA). In
case of violation of homogeneity, Mauchly’s test for equal
variances corrected degrees of freedom and resulting more
conservative p values were used for subsequent analyses. In
case of a statistical significant main effect, further post hoc
testing was conducted using pairwise comparisons with
Bonferroni adjustments for multiple comparisons.
Correlation analyses were performed using Pearson’s correla-
tion. The level of statistical significance was set at p<0.05.
Results
Effects of yohimbine on impulsive decision making
In the DRT, the performance after vehicle administration did
not differ significantly from the last 3 days of baseline training
[preference for large reward day F(3,33) = 0.23, N.S.;
days×delay F(12,132)=0.98, N.S.; start trial omissions F(3,
33) = 1.44, N.S.; choice trial omissions F(3,33) = 0.34,
ε=0.65, N.S.; forced trial omissions F(3,33) = 0.67, N.S.]
(Table 1). Increasing the delays for the large reward signifi-
cantly decreased the mean percentage preference for the large
reward (delay F(4,44) = 93.68, p<0.001; Fig. 1). However,
the main effect of yohimbine on impulsive decision making
did not reach significance [dose F(3,33) = 2.33, p=0.092];
there was a strong significant interaction between the dose
of yohimbine and the delay for the large reward [dose×delay
F(12,132)=3.45, p<0.001]. This indicates that across doses,
yohimbine differentially affected impulsive decision making.
Further post hoc pairwise comparisons revealed that all three
doses of yohimbine significantly increased preference for the
large reward compared to the vehicle condition (all ps<0.05).
In contrast, this decreased preference for the large reward was
not reflected by significant changes in indifference points
(F(3,30)=2.41, p=0.087; Fig. 2). Notably, when the highest
dose of 5 mg/kg yohimbine was administered, 5 out of 12 rats
showed <50 % preference for the large reward during the 0-s
delay trials. The response latencies to start a trial were signif-
icantly altered by yohimbine administration [F(3,33)=12.60,
p<0.001], and further post hoc analyses revealed a significant
increased latency by the highest dose of 5 mg/kg compared to
all other doses (p<0.05; Table 2). Further in-depth analyses
by excluding all animals from the 5-mg/kg yohimbine dose
due to decreased preference for large rewards at 0-s delay and
increased response latency did reveal a strongly significant
Table 1 Baseline parameters of the last three training days before start
of the experiments as measured in the DRT (n = 12)
Baseline
Day 1 Day 2 Day 3
Preference large reward (%) 0 s 85.8 ± 8.6 93.2 ± 3.6 94.5 ± 2.1
5 s 74.2 ± 8.6 67.6 ± 8.9 77.3 ± 8.2
10 s 23.2 ± 7.6 31.6 ± 7.2 27.8 ± 8.3
20 s 7.7 ± 2.5 6.9 ± 1.9 5.8 ± 1.9
40 s 4.4 ± 2.0 3.5 ± 2.4 2.5 ± 1.3
Omission start
(average no. per session)
0.6 ± 0.2 0.6 ± 0.1 0.4 ± 0.1
Omission choice
(average no. per session)
0.6 ± 0.1 0.7 ± 0.2 0.6 ± 0.1
Omission forced trials
(average no. per session)
0.4 ± 0.1 0.3 ± 0.1 0.4 ± 0.1
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increase in indifference point [F(2, 22) = 7.14, p= 0.004].
Additional post hoc pairwise comparisons showed that 1.25
and 2.5 mg/kg yohimbine significantly increased the indiffer-
ence point compared to the vehicle condition (p<0.05).
In order to explore whether yohimbine had differential ef-
fects on the indifference point depending on baseline perfor-
mance under vehicle conditions, correlation analyses were
performed. Neither the effect size of yohimbine on the indif-
ference point, as averaged over the three drug doses, correlat-
ed significantly with vehicle performance [Pearson’s
r=−0.02, N.S.] nor the effect size of each dose of yohimbine
separately revealed a significant correlation with vehicle per-
formance [1.25 mg/kg, Pearson’s r=−0.23, N.S.; 2.5 mg/kg,
Pearson’s r=−0.41, N.S.; 5 mg/kg Pearson’s r=−0.14, N.S.]
(data not shown).
Other task parameters, such as the number of ITI responses
[F(3, 33)=1.79, ε=0.42, N.S.], omitted starts of a trial [F(3,
33) = 2.09, ε = 0.85, N.S.], omitted choice trials [F(3,
33) = 1.71, ε = 0.71, N.S.], or omitted forced trials [F(3,
33)=1.09, N.S.], were not significantly altered by yohimbine
(Table 2).
Effects of yohimbine on response inhibition
Two out of 12 rats were excluded from all analyses based on
their performance in the SST. One rat did not show stable
performance during test days as indicated by a low and highly
variable number of started trials (varying from 16 to 94 % of
the average started trials by the group). A second rat did not
satisfy the race model on two test days (vehicle and 1.25 mg/
kg yohimbine).
The estimated SSRT, the main measure for response
inhibition, did not differ significantly from the last 3 days
of baseline training and performance after vehicle admin-
istration [F(3,27) = 1.74, ε= 0.65, N.S.]. In addition, the
percentage of correctly inhibited responses [days F(3,
27) = 0.82, N.S.; days × delays F(15,135) = 1.65, N.S.]
and the percentage of omitted go trials [F(3,27) = 1.81,
N.S.] were not significantly different between the baseline
and vehicle performance. The mean GoRT was however
significantly increased after vehicle administration com-
pared to basel ine tra in ing days [F(3,27) = 9.90,
p< 0.001]. The post hoc analyses showed that vehicle ad-
ministration significantly increased the mean GoRT com-
pared to two of three baseline days (vehicle 497.0
± 34.0 ms, baseline day 1 470.8 ± 36.2 ms, baseline day
2 466.6 ± 34.2 ms, p< 0.05; Table 3).
The estimated SSRT was significantly altered by yohim-
bine (F(3, 27)=5.06, ε=0.47, p=0.034; Fig. 3). However,
further post hoc analyses revealed no significant differences
between the various doses of yohimbine. In order to explore
whether yohimbine had differential effects on the estimated
SSRT depending on baseline performance under vehicle con-
ditions, a correlation analysis was performed. The analyses of
the effect size of each dose of yohimbine separately revealed a
significant negative correlation for 1.25-mg/kg dose of yohim-
bine (Pearson’s r=−0.76, p=0.011; Fig. 4), whereas the other
doses did not significantly correlate with vehicle SSRT
(2.5 mg/kg, Pearson’s r= 0.14, N.S.; 5 mg/kg, Pearson’s
r=0.60, N.S.).
In addition to its effects on the estimated SSRT, yohimbine
significantly increased the percentage of correctly inhibited
responses (drug F(3,33)=3.42, p=0.028; Fig. 5). Further post
hoc analyses revealed no significant differences between the
various doses of yohimbine. Moreover, the number of omitted
go trials was significantly increased [F(3,27)=10.27, ε=0.70,
p=0.001]. The post hoc comparisons revealed that the highest
dose of 5 mg/kg yohimbine significantly increased the number
of omitted go trials compared to 1.25 (p=0.008) and 2.5 mg/kg
yohimbine (p = 0.028) and thus reduced the number of
Fig. 1 Effects of yohimbine (0, 1.25, 2.5, and 5 mg/kg i.p.) on the mean
percentage preference for the large reward as measured in the DRT
(n = 12). *p< 0.05 vs vehicle condition
Fig. 2 Effects of yohimbine (0, 1.25, 2.5, and 5 mg/kg i.p.) on the mean
indifference point as measured in the DRT (n= 12)
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successful hits (go accuracy) compared to these doses (Fig. 6).
In addition, the mean GoRTwas significantly increased by the
highest dose of yohimbine (F(3,27)=8.97, ε=0.54, p=0.004;
post hoc pairwise comparisons 0 vs 5 mg/kg, p=0.021; 1.25 vs
5 mg/kg, p=0.014; Fig. 7).
Discussion
The current study investigated the effects of acute chal-
lenges with the pharmacological stressor yohimbine on
two distinct forms of impulsive behavior, namely, impulsive
choice and response inhibition. Data indicate that yohim-
bine increased the preference for the large delayed reward in
the DRT, indicating that pharmacologically induced stress
attenuated impulsive choice by increasing self-controlled
choice. By contrast, the measures of response inhibition
capacities in the SST showed a baseline-dependent effect
of the lowest dose of yohimbine on the estimated stop-
signal reaction times. This suggests that pharmacologically
induced stress improves response inhibition in high-
impulsive individuals, whereas response inhibition is de-
creased in low-impulsive individuals.
In the present study, acute yohimbine administration
increased the preference for the large reward. Parameters
measuring aspects of general performance or motivation,
such as the number of omitted trials and response laten-
cies, were not affected, suggesting that there is a specific
effect of yohimbine on decision making as measured in
the DRT. The observation that acute yohimbine decreased
impulsive choice is in line with a recent observation.
Using a similar experimental design, Schwager and co-
workers (2014) showed decrements in impulsive choice
upon yohimbine challenges, using highly palatable soy
emulsion as a reward.
It is hypothesized that acute stress can induce habitual
responding (Schwabe and Wolf 2009). This notion would fit
with previous findings in the DRT indicating that acute yo-
himbine biases choice for the small reward in a descending
delay version of the task (Schwager et al. 2014), i.e., promotes
perseveration for initial action selection as a result of habitual
responding. The present study, however, did not employ a
Table 2 Effects of yohimbine (0,
1.25, 2.5, and 5 mg/kg i.p.) on the
average number of ITI responses,
omissions to start a trial,
omissions during the choice
phase, omissions during the
forced trials, and response
latencies for a small reward and
large reward and to start a trial as
measured in the DRT (n = 12)
Yohimbine (mg/kg)
0 1.25 2.5 5
ITI pokes (average no. per session) 111.2 ± 38.1 175.1 ± 65.0 183.8 ± 92.9 142.7 ± 72.8
Omission start (average no. per session) 0.6 ± 0.2 0.5 ± 0.1 0.8 ± 0.1 1.1 ± 0.3
Omission choice (average no. per session) 0.7 ± 0.2 0.7 ± 0.2 0.8 ± 0.1 1.3 ± 0.4
Omission forced trials (average no. per session) 0.3 ± 0.1 0.5 ± 0.1 0.5 ± 0.1 0.9 ± 0.1
Latency small reward (s) 0.62 ± 0.1 0.66 ± 0.1 1.08 ± 0.2 1.07 ± 0.2
Latency large reward (s) 0.71 ± 0.1 0.70 ± 0.1 0.74 ± 0.1 1.04 ± 0.2
Latency start trial (s) 1.86 ± 0.1 1.55 ± 0.1 1.79 ± 0.2 2.56 ± 0.2*
*p< 0.05 compared to 0, 1.25, and 2.5 mg/kg
Table 3 Baseline parameters of the last three training days before start
of the experiments as measured in the stop-signal task (n = 12)
Baseline
Day 1 Day 2 Day 3
Estimated SSRT
(ms)
0.2 ± 0.0 0.2 ± 0.0 0.2 ± 0.0
Correct inhibition
(%)
0 ms 95.9 ± 2.3 100 ± 0 97.0 ± 1.5
500 ms 97.5 ± 1.7 100 ± 0 96.3 ± 1.9
300 ms 86.3 ± 4.7 85.9 ± 4.4 92.5 ± 3.3
150 ms 57.0 ± 5.0 53.8 ± 5.4 42.3 ± 6.8
75 ms 33.6 ± 5.3 25.7 ± 5.7 27.9 ± 3.6
50 ms 27.7 ± 3.1 34.3 ± 8.3 37.9 ± 5.5
Omitted go trials
(%)
15.8 ± 1.8 18.6 ± 1.4 18.7 ± 1.7
Mean GoRT (ms) 475.5 ± 35.3 470.8 ± 36.2 466.6 ± 34.2 Fig. 3 Effects of yohimbine (0, 1.25, 2.5, and 5 mg/kg i.p.) on the
estimated stop-signal reaction time as measured in the SST (n= 10)
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descending delay version of the DRT. In addition, the different
SSDs in the SSTwere presented in a random order, preventing
the interpretation of habit formation in this latter task.
Therefore, in the present study, effects of habitual responding,
altered reward sensitivity of aversion to delays by yohimbine
cannot be ruled out.
Notably, in the DRT, the highest yohimbine dose of
5 mg/kg revealed decreased preference for the large reward
at 0-s delay trial and, furthermore, increased response laten-
cies to start a trial, which is likely a non-specific effect of this
dose on behavioral performance in the task. Although it re-
mains speculative, this suggests that high doses of yohimbine
have sedative effects or decrease reward sensitivity. In line
with this, increased omission rates at a comparable 5 mg/kg
yohimbine dose have also been reported in the 5-CSRTT (Sun
et al. 2010; Torregrossa et al. 2012). Furthermore, it has been
suggested that yohimbine doses of 5 mg/kg and higher exert
anxiogenic effects (Cole et al. 1995; Singewald et al. 2003;
Sun et al. 2010). In addition, others and the current study show
effects on impulsive behavior with doses lower than 5 mg/kg
(Connolly et al. 2015; Schwager et al. 2014; Sun et al. 2010;
Torregrossa et al. 2012), suggesting that effects of yohimbine
on impulsivity and anxiety are dissociable. Although we did
not assess anxiety-related behavior, our observation that doses
lower than 5 mg/kg did not alter measures of general motiva-
tion or locomotor activity indicates that these doses most like-
ly alter cognitive processes subserving impulsivity, rather than
emotionally driven effects.
Previous work has shown that systemic administration of
yohimbine can induce c-Fos activity in the prefrontal cortex
(PFC) (Singewald et al. 2003). In addition, yohimbine-evoked
increases in impulsive action in 5-CSRTT have been associ-
ated with increased CREB in the orbitofrontal cortex (OFC)
(Sun et al. 2010). Both the PFC and OFC have been shown to
play a crucial and differential role in impulsive action mea-
sured in the 5-CSRTT and impulsive decision making
(Cardinal 2006; Pattij and Vanderschuren 2008; Winstanley
Fig. 4 Effect size as a correlation between the change in SSRT for
1.25 mg/kg yohimbine and baseline SSRT as measured in the SST
(n = 10)
Fig. 5 Effects of yohimbine (0, 1.25, 2.5, and 5 mg/kg i.p.) on the mean
percentage of correctly inhibited stop trials with varying stop-signal
delays before the mean GoRT as measured in the SST (n= 10)
Fig. 6 Effects of yohimbine (0, 1.25, 2.5, and 5 mg/kg i.p.) on the
percentage of omitted go trials as measured in the SST (n = 10). The
number of omitted go trials is expressed as the percentage of total go
trials. *p< 0.05 compared to 1.25 and 2.5 mg/kg
Fig. 7 Effects of yohimbine (0, 1.25, 2.5, and 5 mg/kg i.p.) on the mean
go reaction time asmeasured in the SST (n= 10). *p< 0.05 compared to 0
and 1.25 mg/kg
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2011). For example, medial PFC lesions did not affect prema-
ture responding in the 5-CSRTT (Muir et al. 1996), whereas
medial PFC lesions decreased the preference for the large
reward at the 0-s delay and displayed less delay discounting
compared to controls (Cardinal et al. 2001). Likewise, OFC
lesions were found to decrease impulsive choice (Mar et al.
2011; Winstanley et al. 2004) but were found to increase pre-
mature responding in the 5-CSRTT (Chudasama et al. 2003).
The apparent differential involvement of these brain regions in
impulsive action and impulsive choice is in line with the op-
posite effects of yohimbine in the 5-CSRTT (Sun et al. 2010;
Torregrossa et al. 2012) and the DRT. Although it remains
speculative, this may indicate that the effects of acute yohim-
bine on prefrontal and orbitofrontal cortex functioning might
in part explain the current findings.
Interestingly, in contrast to the findings with yohimbine,
there is limited available evidence of effects of acute non-
pharmacological stress on impulsive decision making. For
example, restraint stress in rats has been shown to decrease
preference for a more costly reward in effort-based decision
making, but this same stress protocol had no effect on delay
discounting (Shafiei et al. 2012). Furthermore, in the same
study, corticosterone administration had no effect on decision
making. Explanations for the discrepancy between the effects
of pharmacological and non-pharmacological stress on impul-
sive behavior might relate to differences between types of
stressors. Although we did not employ this, non-
pharmacological stress can be induced for instance by expo-
sure to pain-related stimuli or social stress that might affect
behavior differently (Armario et al. 1991).
To our knowledge, the current study is the first to investi-
gate the effects of yohimbine on response inhibition in the
SST. The overall analysis of the SST results suggests that
yohimbine decreased aspects of response inhibition, as mea-
sured by increased estimated stop-signal reaction times.
Notably, similar to the DRT, the highest dose of 5 mg/kg
yohimbine induced non-specific behavioral effects in the
SST, by increasing omission rates and increasing reaction
times for the go trials. Thus, this would argue against strong
effects of yohimbine-induced stress on response inhibition per
se. However, since many studies in the SST have shown
baseline-dependent pharmacological effects (de Wit et al.
2002; Eagle et al. 2007; Pattij et al. 2009), further in-depth
correlation analyses indeed revealed a baseline-dependent ef-
fect of yohimbine on response inhibition. These analyses
showed that a low dose of yohimbine improved response in-
hibition in individuals with high-baseline SSRTs but impaired
response inhibition in individuals with low-baseline SSRTs.
Thus, this may suggest that acute stress can exacerbate symp-
toms of impaired impulse control. Although currently limited
to findingsmainly in the 5-CSRTT, it has been shown that trait
impulsivity is related to differences in neurobiological make-
up (Jupp et al. 2013). These effects were specific for the
lowest dose of 1.25 mg/kg yohimbine and were not prevalent
in the other doses. In contrast, no baseline-dependent effects
of yohimbine were found on impulsive choice, suggesting that
acute stress, induced by a low dose of yohimbine, appears to
specifically alter response inhibition in a baseline-dependent
manner.
Response inhibition and delay discounting represent differ-
ent forms of impulsive behavior. The present study corrobo-
rates the findings that both types of behavior do not seem to
correlate in the majority of studies (Broos et al. 2012;
Robinson et al. 2009; Solanto et al. 2001). Impaired action
inhibition, as measured by increased premature responses in
the 5-CSRTT, is yet another form of impulsive behavior
(Robbins 2002). Action inhibition and action cancellation
are considered separate forms of impulsive action. Action in-
hibition as measured in the 5-CSRTT has been shown to be
increased upon yohimbine administration (Sun et al. 2010;
Torregrossa et al. 2012). The current differential effects of
yohimbine on action cancellation and action inhibition further
support dissociations between these measures of impulsivity,
in addition to the dissociation between impulsive action and
impulsive choice.
The noradrenergic system has been implicated to play an
important role in the modulation of stress. Acute stress has
been shown to reduce presynaptic α2 adrenoceptors (Flugge
et al. 2004), thereby increasing noradrenergic signaling
(Abercrombie et al. 1988), which is suggested to be mimicked
by yohimbine. Previous studies have shown that the reinstate-
ment of food and alcohol seeking resulting from comparable
concentrations of yohimbine as used in the current study can
be reversed by antagonizing the corticotrophin-releasing fac-
tor receptor, which plays an important role in the stress re-
sponse (Ghitza et al. 2006; Marinelli et al. 2007). Besides
the modulation of stress, noradrenaline is also implicated in
impulsive behavior (Baarendse and Vanderschuren 2012; Bari
et al. 2009; Pattij and Vanderschuren 2008; Pattij et al. 2012;
Robinson et al. 2007; Winstanley 2011). Specifically, the ben-
eficial effect of noradrenergic reuptake inhibitors in reducing
impulsivity-related symptoms in ADHD has highlighted the
importance of noradrenaline as an important modulator of
impulsive behavior. Moreover, noradrenaline has also been
implicated in other cognitive processes, including working
memory (Arnsten and Jin 2014; Chamberlain et al. 2006)
and behavioral flexibility (Lapiz and Morilak 2006).
Interestingly, the current and earlier reported effects of the
stressor yohimbine seem comparable to the effects of
psychostimulants on impulsive behavior. For instance, impul-
sive choice is attenuated by acute administration of the
psychostimulants cocaine (Winstanley et al. 2007), methyl-
phenidate (van Gaalen et al. 2006b), and amphetamine
(Baarendse and Vanderschuren 2012; van Gaalen et al.
2006b; Winstanley et al. 2005), although some studies have
shown contradicting results in this respect (Cardinal et al.
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2000; Evenden and Ryan 1996; Stanis et al. 2008).
Furthermore, amphetamine and methylphenidate improve re-
sponse inhibition in the SST only in rats with a poor baseline
performance (Eagle et al. 2007; Feola et al. 2000), similar to
the present observations with yohimbine in the SST.
Strikingly, amphetamine (Baarendse and Vanderschuren
2012; Cole and Robbins 1989; Pattij et al. 2007; van Gaalen
et al. 2006a; van Gaalen et al. 2009), methylphenidate
(Milstein et al. 2010; Pattij et al. 2012), cocaine (van Gaalen
et al. 2006a; Winstanley et al. 2007), and nicotine (van Gaalen
et al. 2006a) increase impulsive action as measured in the 5-
CSRTT comparable to the acute effects of yohimbine (Sun et
al. 2010; Torregrossa et al. 2012).
The remarkable similarity between yohimbine and
psychostimulants can be explained by the fact that
psychostimulants have been shown to target both dopaminer-
gic and noradrenergic signaling (Florin et al. 1994; Kuczenski
and Segal 1997; McKittrick and Abercrombie 2007; Ritz and
Kuhar 1989), which is suggested to contribute to their effects
on impulsive behavior (Pattij and Vanderschuren 2008).
Similarly, yohimbine not only elevates noradrenaline signal-
ing but also increases dopamine release (Tanda et al. 1996).
This is in line with the observation that stress leads to in-
creased striatal dopaminergic signaling (Sorg and Kalivas
1991; Wang et al. 2005), resulting in sensitization of dopami-
nergic motivation systems, which are involved in impulsive
behavior and other psychiatric disorders related to stress such
as substance abuse. This in turn may contribute to cross sen-
sitization of stress and psychostimulants or other drugs of
abuse, which is hypothesized to underlie the relation between
stress and increased risk of substance abuse and relapse
(Covington and Miczek 2001; de Jong et al. 2005; Lijffijt et
al. 2014).
A limitation of the current study is that the behavioral ef-
fects of yohimbine may stem from actions of yohimbine at
non-adrenergic receptors such as dopamine and serotonin
(Newman-Tancredi et al. 1998; Tanda et al. 1996).
Therefore, the biological mechanisms underlying the behav-
ioral effects observed here remain speculative. Future research
is needed to determine which neurotransmitter systems specif-
ically are involved in the behavioral effects of yohimbine on
impulsivity. A second possible limitation of this study is that
the effects of yohimbine may be partly attributed to the pos-
sible sedative or motivational effects reflected by the in-
creased omissions and response latencies observed with the
highest dose of yohimbine. Also, as mentioned earlier, yohim-
bine might influence reward sensitivity or delay aversion,
since the highest dose of yohimbine resulted in decreased
preference for the large reward at 0-s delay in the DRT.
Further research is warranted to examine whether these differ-
ent aspects are at play in the effects of yohimbine.
In conclusion, acute systemic administration of the phar-
macological stressor yohimbine decreased impulsive decision
making in the DRT. By contrast, yohimbine exerted baseline-
dependent effects on measures of response inhibition in the
SST. Therefore, the current findings suggest differential in-
volvement of stress in impulsive behavior. Since stress is an
important vulnerability factor for various psychiatric disorders
with comorbid maladaptive impulsivity, the current findings
are valuable and provide further evidence for the multifaceted
nature of impulsivity and its modulation by pharmacological
stress.
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